# A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

> **NCT03088878** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oncternal Therapeutics, Inc** · enrollment: 95 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
- **DRUG:** Cirmtuzumab (300mg) plus Ibrutinib
- **DRUG:** Cirmtuzumab (600 mg) plus ibrutinib
- **DRUG:** Cirmtuzumab (RDR) plus ibrutinib
- **DRUG:** Cirmtuzumab plus ibrutinib
- **DRUG:** Ibrutinib alone

## Key facts

- **NCT ID:** NCT03088878
- **Lead sponsor:** Oncternal Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-03
- **Primary completion:** 2024-09-25
- **Final completion:** 2024-09-25
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-02-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03088878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03088878, "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03088878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*